Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 1999

View Archived Issues

NHLBI awards SBIR grant to Pentose for viral inactivation technology

Enzyme implicated in Alzheimer's disease discovered at SmithKline Beecham

Abgenix and Pfizer add third antigen target to collaboration agreement

Searle acquires two cardiovascular drugs from AstraZeneca in Europe and Scandinavia

Magainin to begin additional clinical trials of squalamine

Lorus Therapeutics completes acquisition of GeneSense

Glaxo Wellcome to market Crystacide in Latin America, Caribbean

Creative BioMolecules reports new data on OP-1 as a treatment for stroke

Promising drug targets in HCV identified by Schering-Plough

Scios licenses FGF rights to Chiron

Icos updates clinical trial program

Remune increases lymphocyte proliferation in HIV infection

FDA advisory panel recommends approval of PMDD treatment

Cantab and Glaxo Wellcome initiate phase II trials for DISC HSV vaccine

Amgen discusses top four late-stage products in pipeline

Synthetic cannabinoids with multiple pharmacological actions

Merck dedicates significant resources to development of nonpeptide GnRH antagonists

Malononitrilamide compound prolongs islet xenograft survival in combination with ciclosporin

Biogen halts all Antova studies following analysis of adverse events

The plot thickens: Pfizer makes surprise counteroffer for Warner-Lambert, files lawsuit

Interaction between FK-506 and prednisolone in islet xenotransplantion model

Breakthrough flu treatment approved by Health Canada

First approval granted for Melacine melanoma therapeutic vaccine

Health Canada approves Vioxx for once-daily treatment of osteoarthritis

U.S. is country of first launch for Raplon

Novel inhibitors of multidrug transporter mediating fluoroquinolone efflux

Manipulation of the cytokine pathway: an effective strategy for preventing pancreatitis?

Diacol is as effective as standard purgative therapy, with better patient preference, compliance

Large clinical trial to evaluate AG-7088 nasal spray as a common cold remedy commences

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...